Weill Cornell Medicine Oncology & Hematology

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
M

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding Assay Could Be Utilized to Select Patients That Are More Likely to Respond to Treatment With PUH71

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Monica Guzman
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Monica Guzman
0 views
May 14, 2020
Comments 0
Login to view comments. Click here to Login
Videos
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
19:17
Weill Cornell Medicine Oncology & Hematology

Inflammatory Breast Cancer - Diagnosis and Management Updates

Feat. M. Cristofanilli
11:23
Weill Cornell Medicine Oncology & Hematology

ASCO® GI 2024 Insights: "The NEST-1 Trial - Neoadjuvant BOT/BAL…

Feat. P. Kasi
31:28
Weill Cornell Medicine Oncology & Hematology

Year in Review: ctDNA in Colorectal Cancer

Feat. P. Kasi
08:59
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in O…

Feat. S. Rutherford
13:16
Weill Cornell Medicine Oncology & Hematology

Monitoring Response to Therapy in mCRPC: What Parameters to Look at

Feat. D. Nanus
23:38
Weill Cornell Medicine Oncology & Hematology

Radiation Combined With IO for the Treatment of SCLC

Feat. A. Saxena
08:25
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase I Dose-Escalation Results of PSMA-T…

Feat. S. Tagawa
08:22
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzum…

Feat. S. Tagawa
05:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare …

Feat. S. Tagawa
07:15
Weill Cornell Medicine Oncology & Hematology

Eltrombopag in ITP: Learnings From the RAISE and EXTEND Trials

Feat. J. Bussel
04:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Stud…

Feat. S. Tagawa
05:48
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and…

Feat. S. Tagawa
12:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cance…

Feat. D. Nanus
29:05
Indy Hematology Review

Aggressive Lymphoma - Nursing and Allied Providers Symposium

Feat. J. Leonard
27:15
Indy Hematology Review

Aggressive B-Cell and T-Cell Lymphomas: Emerging Therapies

Feat. J. Leonard
02:29
Weill Cornell Medicine Oncology & Hematology

CLONEVO: Cell Cycle Inhibition to Target the Evolution of Urothelial…

Feat. B. Faltas
12:11
Weill Cornell Medicine Oncology & Hematology

Pain Management in Sickle Cell Disease

Feat. S. Jain, J. Bussel
11:30
ASCO 2022 Conference Coverage

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophi…

Feat. J. Bussel, C. Mcguinn
09:13
Weill Cornell Medicine Oncology & Hematology

Eltrombopag for the Treatment of Children With Persistent and Chroni…

Feat. J. Bussel
10:29
ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for …

Feat. P. Kasi
06:24
Weill Cornell Medicine Oncology & Hematology

SYK Inhibitors for the Treatment of ITP

Feat. J. Bussel
09:29
i3 Health

Updates in Mantle Cell Lymphoma

Feat. J. Leonard
13:17
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: C…

Feat. S. Tagawa
12:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

Feat. P. Desai
09:55
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

Feat. P. Desai
08:38
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

Feat. P. Desai
10:27
Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

21:36
2021 International Congress on Myeloproliferative Neoplasms

MPN Stem Cell Fitness and the Link to Clinical Outcomes

Feat. J. Scandura
15:12
2021 International Congress on Myeloproliferative Neoplasms

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Ris…

Feat. G. Abu-Zeinah
12:42
2021 International Congress on Myeloproliferative Neoplasms

Pediatric MPNs: An Unfamiliar Topic

Feat. N. Kucine
08:40
Weill Cornell Medicine Oncology & Hematology

WCLC 2021 Data From IMpower010: Characterization of Stage IB-IIIA NS…

Feat. N. Altorki
10:41
ecancer

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

Feat. J. Allan
12:23
Weill Cornell Medicine Oncology & Hematology

Evaluating mCRPC Using 177LU-PNT2002 PSMA Therapy After 2L Hormonal …

Feat. S. Tagawa
11:45
Weill Cornell Medicine Oncology & Hematology

ASCO 2021 Data on PSMA-Targeted Alpha Emitter 225Ac-J591 in Men With…

Feat. S. Tagawa
08:16
Weill Cornell Medicine Oncology & Hematology

Newly FDA-Approved Sacituzumab Govitecan for Advanced Urothelial Car…

Feat. S. Tagawa
15:35
3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

Feat. G. Roboz
09:40
Weill Cornell Medicine Oncology & Hematology

Key Symptoms and HRQoL in Chronic ITP: How Much Does ITP Affect QoL?…

Feat. J. Bussel
12:29
2nd SOHO Italian Conference

Managing Hodgkin Lymphoma: PET Adapted Strategies, Applying ECHELON-…

Feat. J. Leonard
19:44
2nd SOHO Italian Conference

How I Treat DLBCL in 2020: Who Shouldn't Get Standard Treatment…

Feat. .
18:23
Weill Cornell Medicine Oncology & Hematology

2020 Update on TPO Agents: How Effective Are They in Chemotherapy-In…

Feat. J. Bussel
17:03
Weill Cornell Medicine Oncology & Hematology

ITP Receptor Agonists Efficacy Analysis: Romiplostim, Eltrombopag an…

Feat. J. Bussel
20:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

Feat. M. Guzman
18:43
PeerView Oncology

Management of R/R MCL: Ibrutinib and Acalabrutinib Data, Venetoclax …

Feat. J. Ruan
08:56
PeerView Oncology

Management of R/R MCL: Lenalidomide w/ Rituximab & CAR T Therapy

Feat. J. Ruan
21:24
Weill Cornell Medicine Oncology & Hematology

Treatment Options for Older and Elderly Patients With AML: How to Us…

Feat. P. Desai
19:58
12th International Congress on Myeloproliferative Neoplasms

How Should We Treat Children w/ MPN: No Guidelines on Cytoreduction …

Feat. N. Kucine
17:00
12th International Congress on Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-F…

Feat. R. Silver
28:30
12th International Congress on Myeloproliferative Neoplasms

Is There a Role of Transplantation for CML in the Era of TKIs?

Feat. K. Van Besien
22:37
ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP,…

Feat. A. Melnick
33:55
ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

Feat. A. Melnick
40:14
UNMC Leukemia Symposium: Focus on Opportunities to Improve Care

Novel Treatment Options for AML and Overview of Related Trials - Mov…

Feat. G. Roboz
16:17
Indy Hematology Review

Treatment and New Trials in DLBCL - Modifications to R-CHOP Based on…

Feat. J. Leonard
11:24
Indy Hematology Review

Brentuximab Vedotin for Previously Untreated Peripheral T-cell Lymph…

Feat. J. Leonard
05:14
Indy Hematology Review

Axi cell CAR T-cell Therapy for Refractory DLBCL - Overview of ZUMA-…

Feat. J. Leonard